Targeting neurological receptors.
Shah
Saloni
S
Thomson Scientific, Middlesex House, London, UK. saloni.shah@thomson.com
Tear
Steven
S
D000818:Animals; D018491:Dopamine Agonists / Q000494:pharmacology*; D058785:GABA-A Receptor Agonists; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D018377:Neurotransmitter Agents / Q000378:metabolism; D010880:Piperidines / Q000494:pharmacology*; D050638:Receptors, Dopamine D4 / Q000819:agonists*; D058828:Serotonin 5-HT4 Receptor Agonists; D017366:Serotonin Receptor Agonists / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology*
D018491:Dopamine Agonists; D058785:GABA-A Receptor Agonists; D007093:Imidazoles; C430915:LY 404187; D018377:Neurotransmitter Agents; D010880:Piperidines; D058828:Serotonin 5-HT4 Receptor Agonists; D017366:Serotonin Receptor Agonists; D013449:Sulfonamides; D050638:Receptors, Dopamine D4; C504151:1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydroimidazol-2-one